| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sodium, Dietary | 22 | 2023 | 418 | 5.480 |
Why?
|
| Fatty Acids, Omega-3 | 36 | 2023 | 1344 | 4.070 |
Why?
|
| Cardiovascular Diseases | 118 | 2023 | 15160 | 3.930 |
Why?
|
| Primary Prevention | 25 | 2020 | 1167 | 2.440 |
Why?
|
| Cholecalciferol | 23 | 2024 | 535 | 2.360 |
Why?
|
| Risk Assessment | 82 | 2023 | 23336 | 2.160 |
Why?
|
| Dietary Supplements | 59 | 2024 | 3296 | 2.140 |
Why?
|
| Vitamins | 34 | 2024 | 1623 | 2.070 |
Why?
|
| Vitamin D | 41 | 2023 | 3224 | 2.000 |
Why?
|
| Aspirin | 30 | 2018 | 3283 | 1.970 |
Why?
|
| C-Reactive Protein | 40 | 2022 | 3778 | 1.950 |
Why?
|
| Sodium | 14 | 2022 | 1622 | 1.820 |
Why?
|
| Hypertension | 52 | 2023 | 8479 | 1.730 |
Why?
|
| ROC Curve | 15 | 2017 | 3528 | 1.640 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2023 | 3255 | 1.550 |
Why?
|
| Models, Statistical | 31 | 2019 | 5101 | 1.530 |
Why?
|
| Blood Pressure | 41 | 2022 | 8551 | 1.450 |
Why?
|
| Vitamin E | 18 | 2018 | 869 | 1.330 |
Why?
|
| beta Carotene | 17 | 2019 | 527 | 1.280 |
Why?
|
| Women's Health | 25 | 2023 | 2034 | 1.210 |
Why?
|
| Diet, Sodium-Restricted | 11 | 2020 | 287 | 1.180 |
Why?
|
| Stroke | 35 | 2023 | 9981 | 1.050 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2023 | 281 | 1.020 |
Why?
|
| Risk Factors | 166 | 2023 | 72296 | 1.010 |
Why?
|
| Middle Aged | 275 | 2023 | 213390 | 0.950 |
Why?
|
| Platelet Aggregation Inhibitors | 11 | 2018 | 3070 | 0.950 |
Why?
|
| Double-Blind Method | 72 | 2024 | 12025 | 0.940 |
Why?
|
| Lipoproteins | 7 | 2020 | 878 | 0.940 |
Why?
|
| Coronary Disease | 20 | 2020 | 6077 | 0.920 |
Why?
|
| Randomized Controlled Trials as Topic | 39 | 2024 | 9955 | 0.920 |
Why?
|
| Blood Pressure Determination | 11 | 2019 | 633 | 0.900 |
Why?
|
| Mortality | 11 | 2018 | 2864 | 0.860 |
Why?
|
| Female | 320 | 2024 | 380193 | 0.850 |
Why?
|
| Aged | 198 | 2024 | 163288 | 0.830 |
Why?
|
| Humans | 424 | 2024 | 744366 | 0.830 |
Why?
|
| Postmenopause | 18 | 2018 | 2460 | 0.810 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2020 | 1572 | 0.800 |
Why?
|
| Antioxidants | 15 | 2015 | 1659 | 0.760 |
Why?
|
| Risk Reduction Behavior | 8 | 2020 | 1125 | 0.760 |
Why?
|
| Myocardial Infarction | 25 | 2023 | 11718 | 0.750 |
Why?
|
| Vitamin B 6 | 11 | 2018 | 237 | 0.740 |
Why?
|
| Life Style | 19 | 2022 | 3835 | 0.710 |
Why?
|
| Death, Sudden, Cardiac | 14 | 2022 | 1541 | 0.690 |
Why?
|
| Neoplasms | 34 | 2023 | 21696 | 0.680 |
Why?
|
| Predictive Value of Tests | 31 | 2020 | 15078 | 0.680 |
Why?
|
| Proportional Hazards Models | 49 | 2021 | 12356 | 0.660 |
Why?
|
| Incidence | 70 | 2022 | 20952 | 0.660 |
Why?
|
| Diet | 16 | 2020 | 7937 | 0.650 |
Why?
|
| Risk | 40 | 2016 | 9688 | 0.640 |
Why?
|
| Cacao | 3 | 2024 | 98 | 0.640 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 227 | 0.630 |
Why?
|
| Data Interpretation, Statistical | 10 | 2016 | 2716 | 0.620 |
Why?
|
| Biometry | 3 | 2017 | 558 | 0.620 |
Why?
|
| Vitamin B 12 | 11 | 2018 | 527 | 0.620 |
Why?
|
| Sodium Chloride | 2 | 2019 | 625 | 0.610 |
Why?
|
| Follow-Up Studies | 77 | 2022 | 39052 | 0.600 |
Why?
|
| Cholesterol, LDL | 11 | 2022 | 2355 | 0.590 |
Why?
|
| Potassium | 4 | 2022 | 1336 | 0.590 |
Why?
|
| Prospective Studies | 105 | 2023 | 53290 | 0.580 |
Why?
|
| Homocysteine | 8 | 2018 | 647 | 0.580 |
Why?
|
| Coronary Artery Disease | 9 | 2022 | 6486 | 0.580 |
Why?
|
| Male | 189 | 2024 | 350115 | 0.560 |
Why?
|
| Folic Acid | 12 | 2018 | 1300 | 0.560 |
Why?
|
| Decision Support Techniques | 5 | 2016 | 1956 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 22 | 2022 | 11726 | 0.530 |
Why?
|
| Cholesterol, HDL | 11 | 2021 | 1813 | 0.520 |
Why?
|
| Cholesterol | 6 | 2020 | 2919 | 0.520 |
Why?
|
| Hypercholesterolemia | 5 | 2017 | 1151 | 0.510 |
Why?
|
| Vitamin D Deficiency | 7 | 2023 | 1343 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 7 | 2017 | 7282 | 0.510 |
Why?
|
| Polymorphism, Genetic | 12 | 2016 | 4328 | 0.500 |
Why?
|
| Lipoprotein(a) | 2 | 2018 | 435 | 0.490 |
Why?
|
| Atrial Fibrillation | 13 | 2023 | 5035 | 0.480 |
Why?
|
| Smoking | 22 | 2019 | 8987 | 0.480 |
Why?
|
| Ascorbic Acid | 6 | 2009 | 651 | 0.470 |
Why?
|
| United States | 81 | 2022 | 69872 | 0.450 |
Why?
|
| Fatty Acids | 3 | 2023 | 1809 | 0.450 |
Why?
|
| Models, Biological | 7 | 2013 | 9584 | 0.450 |
Why?
|
| Peak Expiratory Flow Rate | 4 | 1995 | 141 | 0.440 |
Why?
|
| Public Health | 4 | 2023 | 2602 | 0.430 |
Why?
|
| Cause of Death | 5 | 2019 | 3582 | 0.430 |
Why?
|
| Phospholipases A2 | 1 | 2012 | 203 | 0.420 |
Why?
|
| Body Mass Index | 34 | 2021 | 12721 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 23 | 2018 | 15520 | 0.410 |
Why?
|
| Inflammation | 16 | 2022 | 10637 | 0.410 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1070 | 0.410 |
Why?
|
| Epidemiologic Methods | 3 | 2011 | 1364 | 0.400 |
Why?
|
| Research Design | 9 | 2020 | 5984 | 0.400 |
Why?
|
| Fish Oils | 5 | 2023 | 470 | 0.400 |
Why?
|
| Models, Theoretical | 2 | 2015 | 3589 | 0.400 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 1342 | 0.390 |
Why?
|
| Diabetes Complications | 4 | 2017 | 1359 | 0.390 |
Why?
|
| Migraine Disorders | 9 | 2023 | 1620 | 0.390 |
Why?
|
| Macular Degeneration | 4 | 2021 | 980 | 0.390 |
Why?
|
| Peptide Fragments | 7 | 2020 | 5096 | 0.390 |
Why?
|
| Motor Activity | 8 | 2015 | 2715 | 0.380 |
Why?
|
| Case-Control Studies | 35 | 2019 | 21748 | 0.380 |
Why?
|
| Weight Loss | 7 | 2018 | 2625 | 0.380 |
Why?
|
| Calibration | 5 | 2019 | 816 | 0.370 |
Why?
|
| Urinalysis | 3 | 2020 | 369 | 0.370 |
Why?
|
| Nutrition Policy | 2 | 2020 | 488 | 0.370 |
Why?
|
| Models, Cardiovascular | 2 | 2007 | 996 | 0.370 |
Why?
|
| Eicosapentaenoic Acid | 5 | 2023 | 582 | 0.370 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2014 | 1131 | 0.360 |
Why?
|
| Logistic Models | 19 | 2017 | 13409 | 0.360 |
Why?
|
| Area Under Curve | 7 | 2017 | 1655 | 0.350 |
Why?
|
| Elasticity | 1 | 2011 | 657 | 0.350 |
Why?
|
| Cohort Studies | 56 | 2023 | 40559 | 0.350 |
Why?
|
| Cognition Disorders | 13 | 2013 | 4043 | 0.350 |
Why?
|
| Fluorobenzenes | 1 | 2011 | 183 | 0.350 |
Why?
|
| Adult | 96 | 2023 | 214052 | 0.350 |
Why?
|
| Exercise | 20 | 2022 | 5615 | 0.340 |
Why?
|
| Evidence-Based Medicine | 3 | 2020 | 3611 | 0.340 |
Why?
|
| Age Factors | 32 | 2021 | 18373 | 0.330 |
Why?
|
| Colorectal Neoplasms | 16 | 2019 | 6773 | 0.330 |
Why?
|
| Potassium, Dietary | 1 | 2009 | 96 | 0.330 |
Why?
|
| Depression | 10 | 2023 | 7759 | 0.310 |
Why?
|
| Prognosis | 30 | 2023 | 29060 | 0.310 |
Why?
|
| Hyperinsulinism | 3 | 2006 | 415 | 0.300 |
Why?
|
| Triglycerides | 5 | 2020 | 2453 | 0.300 |
Why?
|
| Multivariate Analysis | 22 | 2017 | 12244 | 0.300 |
Why?
|
| Urinary Incontinence | 2 | 2022 | 496 | 0.300 |
Why?
|
| Sex Factors | 22 | 2022 | 10400 | 0.300 |
Why?
|
| Cognition | 14 | 2024 | 6770 | 0.300 |
Why?
|
| Peroxidase | 1 | 2010 | 611 | 0.300 |
Why?
|
| Algorithms | 7 | 2023 | 13882 | 0.300 |
Why?
|
| Physical Fitness | 5 | 2013 | 732 | 0.290 |
Why?
|
| Regression Analysis | 14 | 2015 | 6459 | 0.290 |
Why?
|
| Survival Analysis | 6 | 2019 | 10252 | 0.290 |
Why?
|
| Diagnosis | 1 | 2007 | 154 | 0.290 |
Why?
|
| Arteries | 1 | 2011 | 1119 | 0.280 |
Why?
|
| Alcohol Drinking | 14 | 2020 | 3966 | 0.280 |
Why?
|
| Docosahexaenoic Acids | 4 | 2023 | 875 | 0.280 |
Why?
|
| Body Height | 8 | 2018 | 1578 | 0.280 |
Why?
|
| Clinical Medicine | 1 | 2007 | 147 | 0.270 |
Why?
|
| Breast Neoplasms | 17 | 2023 | 20824 | 0.270 |
Why?
|
| Troponin T | 3 | 2017 | 754 | 0.270 |
Why?
|
| Probability | 8 | 2011 | 2506 | 0.270 |
Why?
|
| Time Factors | 29 | 2020 | 40075 | 0.260 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 7914 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2015 | 2282 | 0.250 |
Why?
|
| Coronary Stenosis | 1 | 2010 | 834 | 0.240 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 371 | 0.240 |
Why?
|
| Reproducibility of Results | 14 | 2017 | 19905 | 0.240 |
Why?
|
| Brain Ischemia | 8 | 2020 | 3265 | 0.240 |
Why?
|
| Drug Administration Schedule | 5 | 2014 | 4933 | 0.230 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2004 | 96 | 0.230 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2023 | 3712 | 0.230 |
Why?
|
| Accidental Falls | 2 | 2023 | 1062 | 0.230 |
Why?
|
| Overweight | 6 | 2023 | 2371 | 0.230 |
Why?
|
| alpha-Tocopherol | 2 | 2019 | 127 | 0.230 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2004 | 119 | 0.230 |
Why?
|
| Affect | 2 | 2021 | 1475 | 0.220 |
Why?
|
| Receptors, Estrogen | 3 | 2010 | 2190 | 0.220 |
Why?
|
| Mass Screening | 7 | 2017 | 5253 | 0.220 |
Why?
|
| Preventive Health Services | 2 | 2020 | 575 | 0.220 |
Why?
|
| Thromboembolism | 3 | 2006 | 987 | 0.220 |
Why?
|
| Atherosclerosis | 5 | 2012 | 3444 | 0.220 |
Why?
|
| Obesity | 19 | 2023 | 12746 | 0.210 |
Why?
|
| Linear Models | 13 | 2018 | 5953 | 0.210 |
Why?
|
| Magnesium | 4 | 2006 | 813 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 7 | 2011 | 1159 | 0.210 |
Why?
|
| Longitudinal Studies | 13 | 2019 | 13991 | 0.210 |
Why?
|
| Receptors, Adrenergic, beta-2 | 3 | 2011 | 201 | 0.210 |
Why?
|
| Amino Acids, Branched-Chain | 2 | 2022 | 251 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 4 | 2019 | 357 | 0.210 |
Why?
|
| Vitamin B Complex | 3 | 2008 | 288 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2011 | 1940 | 0.200 |
Why?
|
| Ventricular Function, Left | 5 | 2022 | 3666 | 0.200 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 700 | 0.200 |
Why?
|
| Epistasis, Genetic | 1 | 2004 | 365 | 0.200 |
Why?
|
| Odds Ratio | 14 | 2018 | 9849 | 0.200 |
Why?
|
| Aged, 80 and over | 42 | 2021 | 57776 | 0.200 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 2887 | 0.200 |
Why?
|
| Reference Values | 10 | 2020 | 4982 | 0.190 |
Why?
|
| Health Status | 9 | 2019 | 4034 | 0.190 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2022 | 106 | 0.190 |
Why?
|
| Lipid Metabolism | 3 | 2021 | 1889 | 0.190 |
Why?
|
| Insulin Resistance | 5 | 2021 | 3864 | 0.190 |
Why?
|
| Fasting | 4 | 2020 | 1592 | 0.190 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2012 | 711 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2012 | 2063 | 0.190 |
Why?
|
| Estrogen Replacement Therapy | 8 | 2011 | 1203 | 0.190 |
Why?
|
| Lipids | 5 | 2018 | 3307 | 0.190 |
Why?
|
| Cerebrovascular Disorders | 3 | 2017 | 1504 | 0.190 |
Why?
|
| Genetic Variation | 5 | 2014 | 6542 | 0.190 |
Why?
|
| Fishes | 2 | 2021 | 569 | 0.180 |
Why?
|
| Knee Joint | 2 | 2020 | 1680 | 0.180 |
Why?
|
| Adiponectin | 3 | 2012 | 1101 | 0.180 |
Why?
|
| Computer Simulation | 6 | 2017 | 6194 | 0.180 |
Why?
|
| Body Composition | 2 | 2021 | 2402 | 0.180 |
Why?
|
| Creatinine | 3 | 2015 | 1919 | 0.180 |
Why?
|
| Connective Tissue Diseases | 4 | 2010 | 264 | 0.180 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2011 | 127 | 0.180 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 231 | 0.180 |
Why?
|
| Apolipoprotein E4 | 1 | 2024 | 668 | 0.180 |
Why?
|
| Peripheral Arterial Disease | 3 | 2018 | 1188 | 0.180 |
Why?
|
| Body Weight | 6 | 2018 | 4671 | 0.180 |
Why?
|
| Self Medication | 1 | 2000 | 117 | 0.170 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2020 | 370 | 0.170 |
Why?
|
| Pyrimidines | 1 | 2011 | 2943 | 0.170 |
Why?
|
| Breast Implants | 4 | 2010 | 387 | 0.170 |
Why?
|
| Mammography | 2 | 2009 | 2475 | 0.170 |
Why?
|
| Pain Measurement | 3 | 2020 | 3420 | 0.170 |
Why?
|
| Interleukin-6 | 6 | 2019 | 3203 | 0.170 |
Why?
|
| Fractures, Bone | 3 | 2022 | 1947 | 0.170 |
Why?
|
| Aging | 9 | 2021 | 8664 | 0.160 |
Why?
|
| Depressive Disorder | 3 | 2021 | 3747 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2012 | 4600 | 0.160 |
Why?
|
| Nutritional Requirements | 1 | 2020 | 286 | 0.160 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2004 | 545 | 0.160 |
Why?
|
| Carcinoma, Large Cell | 1 | 2019 | 113 | 0.160 |
Why?
|
| Heart Injuries | 1 | 2020 | 210 | 0.160 |
Why?
|
| Myocardium | 3 | 2020 | 4772 | 0.160 |
Why?
|
| Taiwan | 1 | 2019 | 496 | 0.160 |
Why?
|
| Postprandial Period | 2 | 2020 | 292 | 0.160 |
Why?
|
| Endothelium, Vascular | 4 | 2018 | 4459 | 0.150 |
Why?
|
| Adiposity | 5 | 2021 | 1806 | 0.150 |
Why?
|
| Forecasting | 3 | 2017 | 2951 | 0.150 |
Why?
|
| Treatment Outcome | 21 | 2022 | 63107 | 0.150 |
Why?
|
| Self Report | 3 | 2018 | 3553 | 0.150 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 1660 | 0.150 |
Why?
|
| Bone Density | 4 | 2021 | 3468 | 0.150 |
Why?
|
| Dry Eye Syndromes | 1 | 2022 | 386 | 0.150 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 245 | 0.150 |
Why?
|
| Diet Surveys | 2 | 2020 | 1173 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2009 | 535 | 0.150 |
Why?
|
| Comorbidity | 11 | 2020 | 10388 | 0.150 |
Why?
|
| Sex Characteristics | 6 | 2022 | 2585 | 0.150 |
Why?
|
| Statistics as Topic | 3 | 2016 | 2373 | 0.150 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2012 | 548 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2021 | 10943 | 0.150 |
Why?
|
| Metformin | 2 | 2017 | 836 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2014 | 970 | 0.150 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 129 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2018 | 17446 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 4851 | 0.140 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 167 | 0.140 |
Why?
|
| Electrocardiography | 5 | 2023 | 6442 | 0.140 |
Why?
|
| Placebo Effect | 1 | 2020 | 502 | 0.140 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 238 | 0.140 |
Why?
|
| Policy Making | 1 | 2020 | 554 | 0.140 |
Why?
|
| Diabetes Mellitus | 6 | 2021 | 5749 | 0.140 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 411 | 0.140 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 674 | 0.140 |
Why?
|
| Troponin I | 1 | 2020 | 619 | 0.140 |
Why?
|
| American Heart Association | 3 | 2016 | 1057 | 0.130 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 2703 | 0.130 |
Why?
|
| Calcium | 3 | 2023 | 5755 | 0.130 |
Why?
|
| Treatment Failure | 5 | 2021 | 2618 | 0.130 |
Why?
|
| Depressive Disorder, Major | 2 | 2023 | 4639 | 0.130 |
Why?
|
| Cross-Sectional Studies | 17 | 2023 | 25039 | 0.130 |
Why?
|
| Amino Acid Substitution | 3 | 2005 | 1793 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 817 | 0.130 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 315 | 0.130 |
Why?
|
| Survival Rate | 10 | 2019 | 12788 | 0.130 |
Why?
|
| Glycemic Index | 3 | 2008 | 394 | 0.130 |
Why?
|
| Telomere | 1 | 2021 | 910 | 0.130 |
Why?
|
| Feeding Behavior | 4 | 2020 | 3188 | 0.130 |
Why?
|
| Genotype | 16 | 2024 | 12952 | 0.130 |
Why?
|
| Eating | 2 | 2019 | 1536 | 0.120 |
Why?
|
| Confidence Intervals | 7 | 2013 | 2971 | 0.120 |
Why?
|
| Resistance Training | 1 | 2017 | 164 | 0.120 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 984 | 0.120 |
Why?
|
| Models, Genetic | 2 | 2004 | 3493 | 0.120 |
Why?
|
| Heart Failure | 4 | 2022 | 10895 | 0.120 |
Why?
|
| Chemokines, CC | 2 | 2005 | 291 | 0.120 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 646 | 0.120 |
Why?
|
| Seasons | 2 | 2019 | 1493 | 0.120 |
Why?
|
| Systole | 4 | 2018 | 958 | 0.120 |
Why?
|
| Myocardial Revascularization | 4 | 2020 | 841 | 0.110 |
Why?
|
| Arthralgia | 1 | 2018 | 456 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 592 | 0.110 |
Why?
|
| Directive Counseling | 2 | 2005 | 166 | 0.110 |
Why?
|
| Contraceptives, Oral | 2 | 2007 | 564 | 0.110 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 6489 | 0.110 |
Why?
|
| Tropicamide | 1 | 2012 | 23 | 0.110 |
Why?
|
| Mydriatics | 1 | 2012 | 68 | 0.110 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 15535 | 0.110 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2018 | 489 | 0.110 |
Why?
|
| Gene Frequency | 6 | 2018 | 3587 | 0.110 |
Why?
|
| P-Selectin | 2 | 2005 | 601 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 3 | 2009 | 745 | 0.100 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 13104 | 0.100 |
Why?
|
| Phenylephrine | 1 | 2012 | 301 | 0.100 |
Why?
|
| Antihypertensive Agents | 5 | 2013 | 2047 | 0.100 |
Why?
|
| Aromatase | 1 | 2012 | 147 | 0.100 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 293 | 0.100 |
Why?
|
| Cardiology | 1 | 2023 | 1668 | 0.100 |
Why?
|
| Patient Admission | 1 | 2019 | 1380 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 2166 | 0.100 |
Why?
|
| Parity | 2 | 2018 | 929 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1941 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1993 | 323 | 0.100 |
Why?
|
| Epidemiologic Studies | 5 | 2013 | 676 | 0.100 |
Why?
|
| Health Surveys | 9 | 2020 | 4036 | 0.100 |
Why?
|
| Sample Size | 1 | 2015 | 845 | 0.100 |
Why?
|
| Absorptiometry, Photon | 4 | 2020 | 1725 | 0.100 |
Why?
|
| Osteoarthritis, Knee | 2 | 2020 | 1222 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1373 | 0.100 |
Why?
|
| Drug Combinations | 5 | 2018 | 1958 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 270 | 0.100 |
Why?
|
| Aortic Diseases | 1 | 2017 | 743 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 253 | 0.090 |
Why?
|
| Leisure Activities | 1 | 2012 | 311 | 0.090 |
Why?
|
| Dietary Fats | 2 | 2012 | 2016 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5223 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 159 | 0.090 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2010 | 15 | 0.090 |
Why?
|
| Receptors, Progesterone | 3 | 2010 | 1098 | 0.090 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2010 | 104 | 0.090 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2010 | 707 | 0.090 |
Why?
|
| Seafood | 1 | 2013 | 384 | 0.090 |
Why?
|
| Death | 1 | 2014 | 678 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 2134 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 2104 | 0.090 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 3508 | 0.090 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1989 | 74 | 0.090 |
Why?
|
| Hypoglycemic Agents | 3 | 2017 | 2873 | 0.090 |
Why?
|
| Fibrinogen | 2 | 2010 | 894 | 0.090 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2010 | 142 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2016 | 1184 | 0.090 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2012 | 525 | 0.090 |
Why?
|
| Receptors, Steroid | 1 | 2010 | 155 | 0.090 |
Why?
|
| Metabolomics | 1 | 2018 | 1485 | 0.090 |
Why?
|
| Haplotypes | 4 | 2010 | 2779 | 0.090 |
Why?
|
| Kidney Diseases | 2 | 2011 | 2148 | 0.090 |
Why?
|
| Fruit | 2 | 2005 | 1142 | 0.080 |
Why?
|
| Health Behavior | 2 | 2012 | 2635 | 0.080 |
Why?
|
| Receptors, Interleukin-4 | 2 | 2006 | 65 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1888 | 0.080 |
Why?
|
| Vegetables | 2 | 2005 | 1182 | 0.080 |
Why?
|
| Chemokine CCL11 | 2 | 2005 | 129 | 0.080 |
Why?
|
| Lymphotoxin-alpha | 1 | 2009 | 98 | 0.080 |
Why?
|
| Insulin | 4 | 2010 | 6582 | 0.080 |
Why?
|
| Environmental Monitoring | 1 | 2015 | 1414 | 0.080 |
Why?
|
| Genome, Human | 4 | 2010 | 4420 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13693 | 0.080 |
Why?
|
| Blood Glucose | 4 | 2017 | 6254 | 0.080 |
Why?
|
| Heart Rate | 1 | 2020 | 4092 | 0.080 |
Why?
|
| Heart Diseases | 2 | 2017 | 2789 | 0.080 |
Why?
|
| Sudden Infant Death | 1 | 2011 | 291 | 0.080 |
Why?
|
| Sodium Channels | 1 | 2010 | 349 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 11031 | 0.080 |
Why?
|
| Age Distribution | 3 | 2016 | 2902 | 0.080 |
Why?
|
| Stroke Volume | 4 | 2022 | 5006 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 1739 | 0.080 |
Why?
|
| Retinopathy of Prematurity | 1 | 2012 | 421 | 0.080 |
Why?
|
| Sex Distribution | 3 | 2008 | 2297 | 0.080 |
Why?
|
| Physicians | 8 | 2006 | 4567 | 0.080 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2006 | 275 | 0.080 |
Why?
|
| Diet Records | 2 | 2019 | 425 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 772 | 0.080 |
Why?
|
| Muscles | 2 | 2023 | 1614 | 0.080 |
Why?
|
| Analysis of Variance | 4 | 2010 | 6366 | 0.070 |
Why?
|
| Causality | 2 | 2011 | 1275 | 0.070 |
Why?
|
| Activities of Daily Living | 5 | 2023 | 2419 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2007 | 344 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2014 | 2307 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 1458 | 0.070 |
Why?
|
| Carotenoids | 5 | 1996 | 624 | 0.070 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 3154 | 0.070 |
Why?
|
| Netherlands | 3 | 2020 | 2170 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 6896 | 0.070 |
Why?
|
| Environmental Pollutants | 1 | 2015 | 1179 | 0.070 |
Why?
|
| Selenoprotein P | 1 | 2005 | 32 | 0.070 |
Why?
|
| Nootropic Agents | 1 | 2007 | 160 | 0.070 |
Why?
|
| Respiration Disorders | 1 | 1989 | 371 | 0.070 |
Why?
|
| Parathyroid Hormone | 2 | 2023 | 1800 | 0.070 |
Why?
|
| Alleles | 7 | 2019 | 6933 | 0.070 |
Why?
|
| Lipoprotein Lipase | 1 | 2006 | 126 | 0.070 |
Why?
|
| Neuropsychological Tests | 5 | 2024 | 6994 | 0.070 |
Why?
|
| Venous Thrombosis | 2 | 2006 | 1239 | 0.070 |
Why?
|
| SAIDS Vaccines | 2 | 1998 | 166 | 0.070 |
Why?
|
| Reproductive History | 1 | 2007 | 209 | 0.070 |
Why?
|
| Diastole | 2 | 2000 | 791 | 0.070 |
Why?
|
| Migraine without Aura | 1 | 2006 | 83 | 0.070 |
Why?
|
| Saliva | 2 | 1988 | 809 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2004 | 5692 | 0.070 |
Why?
|
| Prevalence | 9 | 2023 | 15221 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2008 | 1005 | 0.060 |
Why?
|
| Cysteine | 1 | 2010 | 873 | 0.060 |
Why?
|
| Normal Distribution | 1 | 2006 | 280 | 0.060 |
Why?
|
| Patient Compliance | 6 | 2016 | 2684 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 1637 | 0.060 |
Why?
|
| Cost Savings | 1 | 2010 | 925 | 0.060 |
Why?
|
| Patient Selection | 3 | 2016 | 4216 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 2200 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2016 | 4576 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2009 | 1092 | 0.060 |
Why?
|
| Tocopherols | 1 | 2004 | 43 | 0.060 |
Why?
|
| gamma-Linolenic Acid | 1 | 2004 | 16 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 550 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2010 | 1158 | 0.060 |
Why?
|
| Energy Intake | 6 | 2010 | 2148 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 517 | 0.060 |
Why?
|
| Anthropometry | 4 | 2008 | 1350 | 0.060 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2004 | 58 | 0.060 |
Why?
|
| Occupations | 2 | 2005 | 517 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2011 | 1873 | 0.060 |
Why?
|
| Apolipoprotein A-I | 2 | 2020 | 281 | 0.060 |
Why?
|
| Migraine with Aura | 1 | 2006 | 203 | 0.060 |
Why?
|
| Testosterone | 4 | 2012 | 2419 | 0.060 |
Why?
|
| Molecular Weight | 2 | 2020 | 2255 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6539 | 0.060 |
Why?
|
| Child Welfare | 1 | 2008 | 523 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2006 | 305 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 4034 | 0.060 |
Why?
|
| Yohimbine | 1 | 1983 | 62 | 0.060 |
Why?
|
| Prazosin | 1 | 1983 | 96 | 0.060 |
Why?
|
| Oxidative Stress | 4 | 2009 | 3084 | 0.060 |
Why?
|
| Walking | 4 | 2018 | 1180 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1983 | 149 | 0.050 |
Why?
|
| Receptors, Adrenergic | 1 | 1983 | 155 | 0.050 |
Why?
|
| Dexamethasone | 2 | 1988 | 1951 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 941 | 0.050 |
Why?
|
| Minerals | 1 | 2024 | 275 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2010 | 2019 | 0.050 |
Why?
|
| Pravastatin | 1 | 2004 | 395 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2005 | 526 | 0.050 |
Why?
|
| Birth Weight | 1 | 2010 | 2069 | 0.050 |
Why?
|
| Adolescent | 19 | 2013 | 85779 | 0.050 |
Why?
|
| Calcifediol | 1 | 2023 | 166 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2006 | 705 | 0.050 |
Why?
|
| Hydrocortisone | 2 | 1988 | 1826 | 0.050 |
Why?
|
| Headache | 1 | 1989 | 1226 | 0.050 |
Why?
|
| Adenoma | 1 | 2012 | 2174 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 5388 | 0.050 |
Why?
|
| Food Industry | 1 | 2022 | 68 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2006 | 451 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2006 | 544 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2004 | 755 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2009 | 2269 | 0.050 |
Why?
|
| Common Cold | 1 | 2001 | 61 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2005 | 760 | 0.050 |
Why?
|
| Coronary Restenosis | 1 | 2004 | 424 | 0.050 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 1997 | 573 | 0.050 |
Why?
|
| Vitamin A | 1 | 2004 | 615 | 0.050 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2004 | 544 | 0.050 |
Why?
|
| Child | 17 | 2013 | 77709 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 3616 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 1602 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 6234 | 0.050 |
Why?
|
| Placebos | 4 | 2009 | 1676 | 0.050 |
Why?
|
| Silicones | 1 | 2001 | 250 | 0.050 |
Why?
|
| Simian immunodeficiency virus | 3 | 1998 | 846 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 1790 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2003 | 1147 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2000 | 11126 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2001 | 326 | 0.040 |
Why?
|
| Estradiol | 4 | 2012 | 2020 | 0.040 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 7785 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2011 | 3461 | 0.040 |
Why?
|
| Recurrence | 3 | 2020 | 8340 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2009 | 1351 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2023 | 471 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2023 | 604 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2008 | 2575 | 0.040 |
Why?
|
| Glucose | 2 | 2008 | 4398 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 3508 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 230 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2007 | 1161 | 0.040 |
Why?
|
| Apolipoproteins B | 2 | 2011 | 374 | 0.040 |
Why?
|
| Boston | 9 | 2005 | 9312 | 0.040 |
Why?
|
| Intestinal Mucosa | 3 | 1999 | 3037 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
| Femur Neck | 1 | 2020 | 309 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 871 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2024 | 1438 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2007 | 2455 | 0.040 |
Why?
|
| Colonic Neoplasms | 2 | 2000 | 2542 | 0.040 |
Why?
|
| Decision Making | 1 | 2012 | 3888 | 0.040 |
Why?
|
| Lipoproteins, VLDL | 1 | 2018 | 201 | 0.040 |
Why?
|
| Hospitalization | 2 | 2022 | 10259 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2018 | 1609 | 0.040 |
Why?
|
| Ischemia | 1 | 2006 | 1907 | 0.040 |
Why?
|
| Immunization | 2 | 1999 | 1256 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2020 | 5077 | 0.040 |
Why?
|
| Anticholesteremic Agents | 2 | 2018 | 979 | 0.040 |
Why?
|
| Osteoporosis | 2 | 2022 | 1579 | 0.040 |
Why?
|
| Lymph Nodes | 3 | 1999 | 3476 | 0.040 |
Why?
|
| Visual Acuity | 2 | 2017 | 2530 | 0.040 |
Why?
|
| Biological Availability | 1 | 2018 | 397 | 0.040 |
Why?
|
| Gene Products, gag | 1 | 1998 | 337 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2016 | 1683 | 0.040 |
Why?
|
| Immunity, Innate | 2 | 2006 | 2962 | 0.040 |
Why?
|
| Pain | 2 | 2023 | 4988 | 0.040 |
Why?
|
| Heart Bypass, Right | 1 | 1997 | 74 | 0.040 |
Why?
|
| Ontario | 1 | 2018 | 383 | 0.040 |
Why?
|
| Menopause | 4 | 2007 | 1626 | 0.040 |
Why?
|
| Population Surveillance | 3 | 2007 | 2616 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2012 | 6670 | 0.040 |
Why?
|
| Income | 1 | 2005 | 1913 | 0.040 |
Why?
|
| E-Selectin | 2 | 2010 | 579 | 0.040 |
Why?
|
| DNA | 1 | 2010 | 7294 | 0.040 |
Why?
|
| Death, Sudden | 1 | 2018 | 302 | 0.030 |
Why?
|
| Quinazolines | 1 | 1983 | 1356 | 0.030 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2003 | 1018 | 0.030 |
Why?
|
| Blood Pressure Monitors | 1 | 1995 | 33 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 35425 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2018 | 506 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4424 | 0.030 |
Why?
|
| France | 1 | 2017 | 517 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 2 | 2005 | 2647 | 0.030 |
Why?
|
| Child, Preschool | 9 | 2009 | 41005 | 0.030 |
Why?
|
| Weight Gain | 1 | 2006 | 2293 | 0.030 |
Why?
|
| Foundations | 1 | 1995 | 94 | 0.030 |
Why?
|
| Proteins | 1 | 2010 | 6100 | 0.030 |
Why?
|
| Massachusetts | 3 | 2015 | 8662 | 0.030 |
Why?
|
| Animals | 10 | 2021 | 168768 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1999 | 1369 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1998 | 881 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 1431 | 0.030 |
Why?
|
| Endpoint Determination | 2 | 2008 | 601 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 5027 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2001 | 816 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2013 | 2634 | 0.030 |
Why?
|
| Executive Function | 1 | 2023 | 1364 | 0.030 |
Why?
|
| Introns | 2 | 2010 | 992 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2017 | 341 | 0.030 |
Why?
|
| Potassium Chloride | 1 | 1995 | 237 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 29786 | 0.030 |
Why?
|
| Ethanol | 2 | 2005 | 1342 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 638 | 0.030 |
Why?
|
| Demography | 2 | 2009 | 1655 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 636 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 976 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2022 | 955 | 0.030 |
Why?
|
| Palliative Care | 4 | 1997 | 3493 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 12262 | 0.030 |
Why?
|
| Disease Progression | 2 | 2020 | 13286 | 0.030 |
Why?
|
| Endocardial Cushion Defects | 1 | 1993 | 45 | 0.030 |
Why?
|
| Natriuresis | 1 | 1993 | 124 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2012 | 6882 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2006 | 2304 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1996 | 634 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 56429 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 964 | 0.030 |
Why?
|
| Pregnancy | 2 | 2018 | 29144 | 0.030 |
Why?
|
| Homozygote | 2 | 2011 | 1787 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1998 | 952 | 0.030 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 1993 | 63 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2065 | 0.030 |
Why?
|
| Memory | 2 | 2013 | 2174 | 0.030 |
Why?
|
| Sensory Gating | 1 | 2012 | 47 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2010 | 1997 | 0.030 |
Why?
|
| Philadelphia | 1 | 2012 | 267 | 0.030 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 967 | 0.030 |
Why?
|
| Mental Recall | 1 | 2018 | 1206 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 1157 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2013 | 393 | 0.020 |
Why?
|
| Ophthalmic Solutions | 1 | 2012 | 317 | 0.020 |
Why?
|
| Premenopause | 2 | 2007 | 1033 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 2012 | 252 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2012 | 513 | 0.020 |
Why?
|
| Retrospective Studies | 10 | 2019 | 77460 | 0.020 |
Why?
|
| Psychological Tests | 3 | 2007 | 651 | 0.020 |
Why?
|
| Memory Disorders | 2 | 2009 | 1186 | 0.020 |
Why?
|
| Communication | 2 | 2017 | 3750 | 0.020 |
Why?
|
| Phenotype | 3 | 2018 | 16367 | 0.020 |
Why?
|
| Cytokines | 1 | 2005 | 7323 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 1994 | 403 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2013 | 370 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1995 | 1677 | 0.020 |
Why?
|
| Lymphoma | 1 | 1999 | 1877 | 0.020 |
Why?
|
| Health Policy | 1 | 2023 | 2661 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2010 | 70 | 0.020 |
Why?
|
| Women | 1 | 2012 | 230 | 0.020 |
Why?
|
| Indians, North American | 1 | 2014 | 355 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2016 | 1147 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2020 | 1860 | 0.020 |
Why?
|
| Pyridoxal Phosphate | 1 | 2010 | 127 | 0.020 |
Why?
|
| Coronary Artery Bypass | 2 | 2011 | 2288 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1461 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2019 | 2050 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3873 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2011 | 314 | 0.020 |
Why?
|
| Registries | 2 | 2020 | 8091 | 0.020 |
Why?
|
| Insulin, Long-Acting | 1 | 2009 | 57 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 3759 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2009 | 42 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 850 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2013 | 917 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 935 | 0.020 |
Why?
|
| Chemokines | 3 | 1999 | 970 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2016 | 1195 | 0.020 |
Why?
|
| Environment | 1 | 1995 | 1123 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2013 | 592 | 0.020 |
Why?
|
| Austria | 1 | 2009 | 202 | 0.020 |
Why?
|
| Infant | 9 | 2011 | 35134 | 0.020 |
Why?
|
| Femur | 1 | 2015 | 1297 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2008 | 124 | 0.020 |
Why?
|
| Rheumatoid Factor | 1 | 2008 | 188 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1796 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 1216 | 0.020 |
Why?
|
| Beer | 1 | 2008 | 127 | 0.020 |
Why?
|
| Hip Joint | 1 | 2015 | 1002 | 0.020 |
Why?
|
| Culture | 1 | 2012 | 633 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 4222 | 0.020 |
Why?
|
| Suppressor Factors, Immunologic | 2 | 1998 | 68 | 0.020 |
Why?
|
| Brain | 2 | 2012 | 26388 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 244 | 0.020 |
Why?
|
| Wine | 1 | 2008 | 165 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2007 | 54 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 6364 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 2073 | 0.020 |
Why?
|
| Equipment Design | 1 | 1995 | 3582 | 0.020 |
Why?
|
| Markov Chains | 1 | 2010 | 969 | 0.020 |
Why?
|
| Health Personnel | 4 | 2005 | 3219 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2012 | 25628 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 3771 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 862 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1588 | 0.020 |
Why?
|
| Health Literacy | 1 | 2012 | 414 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 1868 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3143 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 2007 | 246 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 781 | 0.020 |
Why?
|
| Apolipoproteins A | 1 | 2006 | 94 | 0.020 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 1990 | 570 | 0.020 |
Why?
|
| Immunoglobulin A | 2 | 2001 | 995 | 0.020 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2012 | 531 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2010 | 789 | 0.020 |
Why?
|
| Bereavement | 1 | 1989 | 278 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1989 | 977 | 0.020 |
Why?
|
| Factor V | 1 | 2006 | 178 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3116 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1999 | 4479 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 1590 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2008 | 535 | 0.020 |
Why?
|
| Health Services for the Aged | 1 | 1988 | 269 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 972 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2715 | 0.020 |
Why?
|
| Melanoma | 2 | 1999 | 5511 | 0.020 |
Why?
|
| Immunity, Mucosal | 2 | 1999 | 490 | 0.020 |
Why?
|
| Thymine | 1 | 2005 | 68 | 0.020 |
Why?
|
| Estrogens | 2 | 2004 | 1566 | 0.020 |
Why?
|
| Plasma | 1 | 2008 | 575 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2010 | 905 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4262 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2010 | 963 | 0.020 |
Why?
|
| Rats | 2 | 2016 | 24252 | 0.020 |
Why?
|
| Macaca mulatta | 3 | 1998 | 2377 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2005 | 167 | 0.020 |
Why?
|
| Angiotensins | 1 | 2005 | 151 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2006 | 3914 | 0.010 |
Why?
|
| Epidemiologic Research Design | 1 | 2007 | 367 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2003 | 59 | 0.010 |
Why?
|
| Menarche | 1 | 2007 | 516 | 0.010 |
Why?
|
| Medicare | 1 | 2022 | 6566 | 0.010 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14723 | 0.010 |
Why?
|
| Mental Health | 1 | 2018 | 3010 | 0.010 |
Why?
|
| Capsules | 1 | 2004 | 196 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 3229 | 0.010 |
Why?
|
| Guanine | 1 | 2005 | 274 | 0.010 |
Why?
|
| Cytosine | 1 | 2005 | 216 | 0.010 |
Why?
|
| Factor VII | 1 | 2003 | 139 | 0.010 |
Why?
|
| Lod Score | 1 | 2004 | 614 | 0.010 |
Why?
|
| Alcoholic Beverages | 1 | 2005 | 265 | 0.010 |
Why?
|
| Leptin | 1 | 2011 | 1600 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 1990 | 1504 | 0.010 |
Why?
|
| Confidentiality | 1 | 2007 | 612 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1983 | 191 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 12207 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 2005 | 317 | 0.010 |
Why?
|
| China | 1 | 2009 | 2245 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 281 | 0.010 |
Why?
|
| BCG Vaccine | 1 | 1985 | 369 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1983 | 174 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2014 | 2071 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 494 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2003 | 202 | 0.010 |
Why?
|
| Vision Disorders | 1 | 1989 | 1058 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1993 | 1622 | 0.010 |
Why?
|
| Europe | 1 | 2009 | 3338 | 0.010 |
Why?
|
| Sunlight | 1 | 1983 | 325 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2010 | 2488 | 0.010 |
Why?
|
| Educational Status | 2 | 2005 | 2540 | 0.010 |
Why?
|
| Mice | 2 | 2020 | 81201 | 0.010 |
Why?
|
| Home Care Services | 1 | 1988 | 606 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1983 | 2186 | 0.010 |
Why?
|
| Dairy Products | 1 | 2005 | 498 | 0.010 |
Why?
|
| HIV-1 | 1 | 1999 | 6939 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2001 | 102 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 611 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2015 | 4232 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1991 | 1887 | 0.010 |
Why?
|
| Complement C4 | 1 | 2001 | 257 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 1460 | 0.010 |
Why?
|
| Alzheimer Disease | 2 | 1993 | 8038 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2001 | 402 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 2001 | 355 | 0.010 |
Why?
|
| Adenine | 1 | 2005 | 936 | 0.010 |
Why?
|
| Heart Defects, Congenital | 2 | 1994 | 4583 | 0.010 |
Why?
|
| Psychometrics | 1 | 2008 | 3003 | 0.010 |
Why?
|
| Complement C3 | 1 | 2001 | 461 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1983 | 642 | 0.010 |
Why?
|
| Intracranial Hemorrhages | 1 | 2005 | 855 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1985 | 810 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 2439 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2004 | 2421 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 2001 | 4561 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 2804 | 0.010 |
Why?
|
| Reoperation | 3 | 1993 | 4201 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2012 | 9145 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 4185 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2012 | 6151 | 0.010 |
Why?
|
| Urban Population | 1 | 1985 | 2022 | 0.010 |
Why?
|
| Quality of Life | 3 | 2012 | 12802 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2758 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 2428 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1988 | 2690 | 0.010 |
Why?
|
| Antibody-Producing Cells | 1 | 1996 | 143 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2001 | 1537 | 0.010 |
Why?
|
| Respiration | 1 | 1982 | 1653 | 0.010 |
Why?
|
| Genome | 1 | 2004 | 1807 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2001 | 865 | 0.010 |
Why?
|
| Pediatrics | 1 | 2009 | 3475 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2009 | 7730 | 0.010 |
Why?
|
| Nurses | 1 | 2004 | 2462 | 0.010 |
Why?
|
| Medical Records | 1 | 1999 | 1413 | 0.010 |
Why?
|
| Binding Sites | 1 | 1983 | 6111 | 0.010 |
Why?
|
| Ileum | 1 | 1996 | 565 | 0.010 |
Why?
|
| Extrapyramidal Tracts | 1 | 1993 | 18 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 2375 | 0.010 |
Why?
|
| Methods | 1 | 1993 | 1129 | 0.010 |
Why?
|
| Rectum | 1 | 1998 | 904 | 0.010 |
Why?
|
| Counseling | 1 | 2001 | 1523 | 0.010 |
Why?
|
| HIV Infections | 1 | 1999 | 16715 | 0.010 |
Why?
|
| Hospital Mortality | 2 | 1997 | 5316 | 0.010 |
Why?
|
| Cranial Nerve Diseases | 1 | 1993 | 112 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1993 | 264 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 1999 | 1322 | 0.010 |
Why?
|
| Pupil | 1 | 1993 | 149 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20130 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1986 | 3537 | 0.010 |
Why?
|
| Reflex | 1 | 1993 | 365 | 0.010 |
Why?
|
| Social Support | 1 | 2001 | 2118 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2003 | 3280 | 0.010 |
Why?
|
| Sensation | 1 | 1993 | 336 | 0.010 |
Why?
|
| Pyramidal Tracts | 1 | 1993 | 256 | 0.010 |
Why?
|
| Fontan Procedure | 1 | 1997 | 776 | 0.010 |
Why?
|
| Genomics | 1 | 2006 | 5717 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2001 | 2897 | 0.010 |
Why?
|
| Arm | 1 | 1993 | 589 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1998 | 10183 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1997 | 1403 | 0.010 |
Why?
|
| Disease | 1 | 1995 | 680 | 0.010 |
Why?
|
| Truth Disclosure | 1 | 1993 | 436 | 0.010 |
Why?
|
| Lymphatic System | 1 | 1990 | 252 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1990 | 249 | 0.010 |
Why?
|
| Air Pollution | 1 | 1982 | 2286 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1990 | 915 | 0.000 |
Why?
|
| Fluorescent Dyes | 1 | 1996 | 1917 | 0.000 |
Why?
|
| Sampling Studies | 1 | 1989 | 623 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1993 | 1000 | 0.000 |
Why?
|
| Syndrome | 1 | 1994 | 3252 | 0.000 |
Why?
|
| Leg | 1 | 1993 | 1116 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1990 | 389 | 0.000 |
Why?
|
| Gait | 1 | 1993 | 793 | 0.000 |
Why?
|
| Comprehensive Health Care | 1 | 1988 | 127 | 0.000 |
Why?
|
| Marriage | 1 | 1988 | 339 | 0.000 |
Why?
|
| Promoter Regions, Genetic | 1 | 1998 | 5867 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 5524 | 0.000 |
Why?
|
| Mental Processes | 1 | 1988 | 249 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1986 | 6598 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5856 | 0.000 |
Why?
|
| Movement | 1 | 1993 | 1471 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3177 | 0.000 |
Why?
|
| Colombia | 1 | 1985 | 258 | 0.000 |
Why?
|
| Adipose Tissue, Brown | 1 | 1990 | 756 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 9274 | 0.000 |
Why?
|
| Long-Term Care | 1 | 1988 | 607 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1986 | 936 | 0.000 |
Why?
|
| Blister | 1 | 1983 | 86 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1990 | 1357 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1996 | 4666 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 8642 | 0.000 |
Why?
|
| Sunburn | 1 | 1983 | 155 | 0.000 |
Why?
|
| Interviews as Topic | 1 | 1989 | 2539 | 0.000 |
Why?
|
| Sulfur Dioxide | 1 | 1982 | 177 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1990 | 1170 | 0.000 |
Why?
|
| Ohio | 1 | 1982 | 337 | 0.000 |
Why?
|
| Skin Pigmentation | 1 | 1983 | 282 | 0.000 |
Why?
|
| Social Class | 1 | 1990 | 1997 | 0.000 |
Why?
|
| Pulmonary Veins | 1 | 1986 | 761 | 0.000 |
Why?
|
| Vital Capacity | 1 | 1982 | 925 | 0.000 |
Why?
|
| Pulmonary Artery | 1 | 1986 | 1912 | 0.000 |
Why?
|
| Forced Expiratory Volume | 1 | 1982 | 1745 | 0.000 |
Why?
|
| Kidney | 1 | 1990 | 7184 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1993 | 15297 | 0.000 |
Why?
|